These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 26952809)

  • 1. Pharmacogenomics strategies to optimize treatments for multiple sclerosis: Insights from clinical research.
    Grossman I; Knappertz V; Laifenfeld D; Ross C; Zeskind B; Kolitz S; Ladkani D; Hayardeny L; Loupe P; Laufer R; Hayden M
    Prog Neurobiol; 2017 May; 152():114-130. PubMed ID: 26952809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenomics and multiple sclerosis: moving toward individualized medicine.
    Comabella M; Vandenbroeck K
    Curr Neurol Neurosci Rep; 2011 Oct; 11(5):484-91. PubMed ID: 21701907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Genetic Markers for Personalized Therapy of Polygenic Diseases: Pharmacogenetics of Multiple Sclerosis].
    Tsareva EY; Favorova OO; Boyko AN; Kulakova OG
    Mol Biol (Mosk); 2019; 53(4):574-599. PubMed ID: 31397433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple sclerosis: pharmacogenomics and personalised drug treatment.
    Annibali V; Ristori G; Cannoni S; Romano S; Visconti A; Ghazaryan A; Figà Talamanca L; Salvetti M; Mechelli R
    Neurol Sci; 2006 Sep; 27 Suppl 5():S347-9. PubMed ID: 16998717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetics of multiple sclerosis: personalized therapy with immunomodulatory drugs.
    Tsareva E; Kulakova O; Boyko A; Favorova O
    Pharmacogenet Genomics; 2016 Mar; 26(3):103-15. PubMed ID: 26678572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenomics of multiple sclerosis: in search for a personalized therapy.
    Martinez-Forero I; Pelaez A; Villoslada P
    Expert Opin Pharmacother; 2008 Dec; 9(17):3053-67. PubMed ID: 19006478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenomics of IFN-beta in multiple sclerosis: towards a personalized medicine approach.
    Vosslamber S; van Baarsen LG; Verweij CL
    Pharmacogenomics; 2009 Jan; 10(1):97-108. PubMed ID: 19102719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rs205764 and rs547311 in linc00513 may influence treatment responses in multiple sclerosis patients: A pharmacogenomics Egyptian study.
    Amin NS; Abd El-Aziz MK; Hamed M; Moustafa RR; El Tayebi HM
    Front Immunol; 2023; 14():1087595. PubMed ID: 36883100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. United Europeans for development of pharmacogenomics in multiple sclerosis network.
    Vandenbroeck K; Comabella M; Tolosa E; Goertsches R; Brassat D; Hintzen R; Infante-Duarte C; Favorov A; Escorza S; Palacios R; Oksenberg JR; Villoslada P
    Pharmacogenomics; 2009 May; 10(5):885-94. PubMed ID: 19450134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Ubiquitous Pharmacogenomics consortium: making effective treatment optimization accessible to every European citizen.
    Manson LE; van der Wouden CH; Swen JJ; Guchelaar HJ
    Pharmacogenomics; 2017 Jul; 18(11):1041-1045. PubMed ID: 28685652
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacogenomics of interferon-β in multiple sclerosis: what has been accomplished and how can we ensure future progress?
    Carlson RJ; Doucette JR; Knox K; Nazarali AJ
    Cytokine Growth Factor Rev; 2015 Apr; 26(2):249-61. PubMed ID: 25524087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenomic update on multiple sclerosis: a focus on actual and new therapeutic strategies.
    Foti Cuzzola V; Palella E; Celi D; Barresi M; Giacoppo S; Bramanti P; Marino S
    Pharmacogenomics J; 2012 Dec; 12(6):453-61. PubMed ID: 23044601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenomics of the response to IFN-beta in multiple sclerosis: ramifications from the first genome-wide screen.
    Vandenbroeck K; Matute C
    Pharmacogenomics; 2008 May; 9(5):639-45. PubMed ID: 18466107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple sclerosis pharmacogenomics: maximizing efficacy of therapy.
    Pappas DJ; Oksenberg JR
    Neurology; 2010 Jan; 74 Suppl 1():S62-9. PubMed ID: 20038765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis.
    Ross CJ; Towfic F; Shankar J; Laifenfeld D; Thoma M; Davis M; Weiner B; Kusko R; Zeskind B; Knappertz V; Grossman I; Hayden MR
    Genome Med; 2017 May; 9(1):50. PubMed ID: 28569182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Translation towards personalized medicine in Multiple Sclerosis.
    Miller A; Avidan N; Tzunz-Henig N; Glass-Marmor L; Lejbkowicz I; Pinter RY; Paperna T
    J Neurol Sci; 2008 Nov; 274(1-2):68-75. PubMed ID: 18789804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What's new about oral treatments in Multiple Sclerosis? Immunogenetics still under question.
    Pistono C; Osera C; Boiocchi C; Mallucci G; Cuccia M; Bergamaschi R; Pascale A
    Pharmacol Res; 2017 Jun; 120():279-293. PubMed ID: 28396093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomics and proteomics: role in the management of multiple sclerosis.
    Kappos L; Achtnichts L; Dahlke F; Kuhle J; Naegelin Y; Sandbrink R; Lindberg RL
    J Neurol; 2005 Sep; 252 Suppl 3():iii21-iii27. PubMed ID: 16170496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate.
    Kulakova OG; Tsareva EY; Lvovs D; Favorov AV; Boyko AN; Favorova OO
    Pharmacogenomics; 2014 Apr; 15(5):679-85. PubMed ID: 24798724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.